QTRX Stock — Quanterix Corp

Up next

Next earnings call

Nov 14, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Aug 10, 2026

Q2 2026 earnings call transcript

call held Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$153.41M

Trailing 12 months

Net income (TTM)

−$123.11M

Trailing 12 months

Revenue growth YoY

+34.4%

Year over year

Operating margin

-99.6%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+21.3%

Year over year · more shares

Price change (1Y)

-35.6%

Trailing year

Short interest

10.5%

Latest settlement · 4.2 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg −14%

below

Price vs 50-day avg +19%

above

RSI (14) 63

neutral

MACD trend Positive

52-week position 22%

mid-range

Momentum

relative strength

Neutral

1-month return +41%

trailing

6-month return +7%

trailing

YTD return −43%

this year

Relative strength −5%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Accumulating

+4% holders QoQ · +37 funds added

Insider flow Accumulating

Net +$286.4K over 90 days · 0% sells

Short interest Rising

10.52% of float · ▲ +3.3% MoM · 4.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

133 holders — mid 3-yr range

Squeeze score 70

high risk · 0–100

Fundamentals

Strong

Revenue growth +65%

Y/Y

Gross margin 173%

contracting

EPS growth −151%

Y/Y

Free cash flow $-79.8M

Balance sheet $173.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 92%

annualized · 1-yr

Max drawdown −70%

past year

ATR 6.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 10, 2026

2026

Revenues $142M – $148M

prior FY $138.9M midpoint +4.4% Y/Y

Non-GAAP gross margins Non-GAAP 48% – 50%

2026 year-end cash balance $80M

Full Year 2026

Adjusted gross margin (non-GAAP) Non-GAAP Initiated 48% – 50%

Cash balance at year-end Initiated $80M

Guided vs delivered · last 1 settled

2024 revenue guidance 2024 Full Year

guided $134M – $138M

guided $134M – $138M $137.42M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−14% Bearish

Price vs 50-day avg

+19% Bullish

RSI (14)

63 Neutral

MACD trend

Positive Bullish

52-week position

22% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $3 › 200d $4 — 200d above 50d

Institutional flow Accumulating

+4% holders QoQ · +37 funds added

Insider flow Accumulating

Net +$286.4K over 90 days · 0% sells

Short interest Rising

10.52% of float · ▲ +3.3% MoM · 4.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

133 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $2 Now $4 · 22% Range high $8

vs 200-day avg -14% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted cash usage non-GAAP	$4M	Q2 2026	—
GAAP → non-GAAP reconciliation GAAP Cash usage -5.73M +1.09M Acquisition and integration related payments +649K Payment of employee separation costs = Adjusted cash usage -3.99M
Adjusted cash usage (non-GAAP) non-GAAP	-$18.76M	Six Months Ended June 30, 2026	—
Adjusted EBITDA (non-GAAP) non-GAAP	-$9.99M	Three Months Ended June 30, 2026	—
Adjusted EBITDA (non-GAAP) loss non-GAAP	$10M	Q2 2026	—
Adjusted EBITDA margin (non-GAAP) non-GAAP	-30.4%	Three Months Ended June 30, 2026	—
Adjusted gross margin (non-GAAP) non-GAAP	47.9%	Q2 2026	—
Adjusted gross profit (non-GAAP) non-GAAP	$15.76M	Three Months Ended June 30, 2026	—
GAAP → non-GAAP reconciliation GAAP Gross profit 12.67M +203K Purchase accounting impact on inventory and property and equipment +2.89M Amortization of acquired intangible assets = Adjusted gross profit (non-GAAP) 15.76M
Adjusted loss from operations (non-GAAP) non-GAAP	-15.99M	Q2 FY2026	—
Adjusted total operating expenses (non-GAAP) non-GAAP	$31.75M	Three Months Ended June 30, 2026	—
Cash Balance	$97M	Q2 2026	—
Cash, cash equivalents, marketable securities, and restricted cash	$96.9M	Q2 2026	—
GAAP gross margin	38.5%	Q2 2026	—
Goodwill impairment charge	$26.9M	the three months ended June 30, 2026 filing	—
Instruments placed, cumulative (Spatial)	776	2026 YTD	—
Integration and employee separation costs non-GAAP	$1.7M	Q2 2026	—
Publications, cumulative (Simoa)	6,845	2026 YTD	—
Savings from Akoya acquisition integration	$85M	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
QTRX Quanterix Corp this stock	$154.65M	-42.8%	+64.5%	—	10.5%
ABT Abbott Laboratories	$174.90B	-22.2%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-10.1%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-21.6%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-55.3%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

133

% held: 62.8%
Net QoQ: -6.8M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

126

View

Short & Settlement

Short Interest Rising

Shares short

5.0M

Days to cover: 4.2d
Change: +159.2K sh

View

Short Volume

Short vol %

58%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

531

Value: $1.4K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

62.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$286.4K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$138.9M

Net income (FY): $-107.2M
EPS diluted: $-2.51

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 12, 2026
This year: 14

View

Proposed Sales

Value

$378.1K

Shares: 20.9K
Filed: Jun 12, 2024

View

Earnings & Events

Webcasts

Last webcast

Aug 12, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
QTRX	+11.3%	+41.1%	+7.4%	-1.9%	-42.8%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+11.5%	+41.6%	-4.8%	-2.8%	-55.6%

QTRX · Quanterix Corp

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance